Targeting KRAS-Mutant Non-Small-Cell Lung Cancer: One Mutation at a Time, With a Focus on KRAS G12C Mutations.

Abstract

Article Tools BIOLOGY OF NEOPLASIA Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Purchase Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.20.00744 Journal of Clinical Oncology - published online before print October 26, 2020 PMID: 33104438 Targeting KRAS-Mutant Non–Small-Cell Lung Cancer: One Mutation at a Time, With a Focus on KRAS G12C Mutations Timothy F. Burns, MD, PhD1xTimothy F. BurnsSearch for articles by this author; Hossein Borghaei , MS, DO2xHossein BorghaeiSearch for articles by this author; Suresh S. Ramalingam , MD3xSuresh S. RamalingamSearch for articles by this author; Tony S. Mok, MD4xTony S. MokSearch for articles by this author; and Solange Peters , MD, PhD5xSolange PetersSearch for articles by this author Show More 1University of Pittsburgh Medical Center (UPMC) Hillman Cancer Center, Pittsburgh, PA2Fox Chase Cancer Center, Philadelphia, PA3Division of Medical Oncology, Emory University School of Medicine, Winship Cancer Institute, Atlanta, GA4State Laboratory of Translational Oncology, Department of Clinical Oncology, The Chinese University of Hong Kong, Hong Kong5Department of Oncology, Centre Hospitalier Universitaire Vaudois, Lausanne University, Switzerland https://doi.org/10.1200/JCO.20.00744 First Page Full Text PDF Figures and Tables © 2020 by American Society of Clinical OncologySUPPORTSupported by Amgen.AUTHOR CONTRIBUTIONSConception and design: All authorsAdministrative support: Tony S. MokCollection and assembly of data: All authorsData analysis and interpretation: All authorsProvision of study material or patients: All authorsManuscript writing: All authorsFinal approval of manuscript: All authorsAccountable for all aspects of the work: All authorsAUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTERESTTargeting KRAS-Mutant Non–Small-Cell Lung Cancer: One Mutation at a Time, With a Focus on KRAS G12C MutationsThe following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/authors/author-center.Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).Timothy F. BurnsConsulting or Advisory Role: AbbVie/Stemcentrx, Blueprint Medicines, Novartis, Thermo Fisher ScientificHossein BorghaeiHonoraria: Bristol Myers Squibb, Celgene, Axiom Biotechnologies, PfizerConsulting or Advisory Role: Bristol Myers Squibb, Lilly, Celgene, Genentech, Pfizer, Boehringer Ingelheim, EMD Serono, Trovagene, Novartis, Merck, AstraZeneca, Genmab, Regeneron, Cantargia, BioNTech, AbbVie, PharmaMar, Takeda, Amgen, HUYA Bioscience International, Sonnetbio, RgenixResearch Funding: Millennium (Inst), Merck (Inst), Celgene (Inst), Bristol Myers Squibb (Inst), Lilly (Inst)Travel, Accommodations, Expenses: Bristol Myers Squibb, Lilly, Clovis Oncology, Celgene, Genentech, Novartis, Merck, AmgenOther Relationship: University of Pennsylvania, Takeda, IncyteSuresh S. RamalingamConsulting or Advisory Role: Amgen, Boehringer Ingelheim, Celgene, Genentech/Roche, Lilly/ImClone, Bristol Myers Squibb, AstraZeneca, AbbVie, Merck, Takeda, Tesaro, Nektar, LoxoResearch Funding: AbbVie (Inst), Bristol Myers Squibb (Inst), Pfizer (Inst), Merck (Inst), AstraZeneca/MedImmune (Inst), Vertex (Inst), Takeda (Inst), EMD Serono (Inst), Genmab (Inst), Advaxis (Inst), Amgen (Inst)Travel, Accommodations, Expenses: AstraZenecaTony S. MokEmployment: The Chinese University of Hong KongLeadership: Sanomics, Hutchison MediPharma, AstraZenecaStock and Other Ownership Interests: Sanomics, Hutchison MediPharmaHonoraria: AstraZeneca, Roche/Genentech, Lilly, Bristol Myers Squibb, Boehringer Ingelheim, Novartis, Merck Sharp & Dohme, Pfizer, Merck Serono, SFJ Pharmaceuticals Group, ACEA Biosciences, Vertex, Celgene, Ignyta, Fishawack Facilitate, Takeda, Janssen, Hutchison MediPharmaConsulting or Advisory Role: AstraZeneca, Roche/Genentech, Lilly, Merck/Serono, Bristol Myers Squibb, Pfizer, Boehringer Ingelheim, Novartis, Clovis Oncology, Vertex, SFJ Pharmaceuticals Group, ACEA Biosciences, Merck Sharp & Dohme, geneDecode, Oncogenex, Celgene, Ignyta, Cirina, Hutchison MediPharmaResearch Funding: AstraZeneca (Inst), Boehringer Ingelheim (Inst), Pfizer (Inst), Novartis (Inst), SFJ Pharmaceuticals Group (Inst), Roche (Inst), Merck Sharp & Dohme (Inst), Clovis Oncology (Inst), Bristol Myers Squibb (Inst), Xcovery (Inst)Solange PetersHonoraria: Roche (Inst), Bristol Myers Squibb (Inst), Novartis (Inst), Pfizer (Inst), MSD (Inst), AstraZeneca (Inst), Boehringer Ingelheim, Takeda (Inst), Illumina (Inst)Consulting or Advisory Role: Roche/Genentech (Inst), Novartis (Inst), Bristol Myers Squibb (Inst), Pfizer (Inst), MSD (Inst), Amgen (Inst), AstraZeneca (Inst), Janssen (Inst), Regeneron (Inst), Merck Serono (Inst), Boehringer Ingelheim (Inst), Takeda (Inst), Lilly (Inst), AbbVie (Inst), Bayer (Inst), Biocartis (Inst), Debiopharm Group (Inst), Illumina (Inst), PharmaMar, Sanofi (Inst), Seattle Genetics (Inst), Blueprint Medicines (Inst), Daiichi Sankyo (Inst), Incyte (Inst), Bioinvent (Inst), Clovis Oncology (Inst), Vaccibody (Inst)Research Funding: Roche (Inst), Bristol Myers Squibb (Inst), MSD (Inst), Amgen (Inst), Lilly (Inst), AstraZeneca (Inst), Pfizer (Inst), Illumina (Inst), Merck Serono (Inst), Novartis (Inst), Biodesix (Inst), Boehringer Ingelheim (Inst), Iovance Biotherapeutics (Inst)Travel, Accommodations, Expenses: Roche, Bristol Myers Squibb, MSD, Sanofi, IncyteUncompensated Relationships: JTO Deputy Editor, ESMO President 20/21, ETOP Scientific Coordinator, Annals of Oncology associate editor (I)No other potential conflicts of interest were reported.